Treatment‐specific differences in soluble B‐cell maturation antigen levels at minimum residual disease negativity in multiple myeloma

Key Points

• This research aims to investigate the differences in soluble B-cell maturation antigen levels in multiple myeloma at minimum residual disease negativity based on treatment type.
• Data from multiple myeloma patients was analyzed regarding soluble B-cell maturation antigen levels.
• Comparative assessments were made based on various treatment regimens.
• Significant variations in soluble B-cell maturation antigen levels were observed across different treatments.